Navigation Links
Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
Date:5/11/2011

DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that positive preclinical data will be presented at the EuroPCR conference in Paris, France on May 18, 2011 in a presentation titled, "MiStent DES: A Novel Third Generation DES with a Fully-absorbable Coating and Enhanced Drug Delivery Capabilities." The MiStent Drug-Eluting Coronary Stent System ("MiStent DES") is an ultra-thin, advanced alloy drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation.

In a porcine coronary model, data show continuous and controlled release of sirolimus, with the MiStent DES coating being eliminated from the stent within 45 to 60 days, and fully absorbed in the tissue by 90 days following implant. Preclinical studies additionally demonstrated a positive indication of safety with lower inflammation observed from the MiStent DES compared to the bare metal Abbott MULTI-LINK Vision™ Coronary Stent at 30 and 90 days in the challenging overlapping stents implant configuration.

James B. McClain, Ph.D., Senior Vice President of Micell, said, "Micell is uniting well-known DES stent components with a proprietary coating process to produce a fundamentally different DES. Our preclinical studies demonstrate a markedly consistent drug delivery profile with controlled, linear release of therapeutic levels of drug."

Clinical trials of the MiStent DES include DESSOLVE I, a study of 30 patients with documented stable or unstable angina pectoris or ischemia, which completed enrollment earlier this year. The primary endpoint is in-stent late lumen loss, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm long stent. DESSOLVE II is an ongoing multi-center study of approximately 270 patients with documented stable or unstable angina pectoris or ischemia. The primary endpoint is superiority of MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® Sprint DES, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 30 mm long stent.

Elazer R. Edelman, M.D., Ph.D., commented, "The presented data, based on a thorough preclinical evaluation, validate the premise that Micell's unique coating process could produce a remarkable level of consistency and control in a drug-eluting stent." Dr. Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at the Massachusetts Institute of Technology and is a consultant to Micell.

Presentation Details

EuroPCR, Paris, France -- Wednesday, May 18, 15:00-16:30
Plenary session: Cardiovascular Innovation Pipeline – Coronary Heart Disease
MiStent DES: A Novel Third Generation DES with a Fully-absorbable Coating and Enhanced Drug Delivery Capabilities
Presented by James B. McClain, Ph.D., Senior Vice President, Micell Technologies

About the MiStent DES

The MiStent DES is a drug-eluting stent designed to optimize healing. Micell's rapid-absorbing drug/polymer formulation is intended to precisely and consistently control drug elution and polymer exposure duration. The MiStent DES is intended to deliver a precise therapeutic solution for coronary artery disease with the potential to avoid the long-term safety concerns associated with current drug-eluting stents.

Using an approved drug (sirolimus) and polymer (PLGA), Micell's patented supercritical fluid technology allows a rigorously controlled drug/polymer coating to be applied to a bare-metal stent. The MiStent DES leverages the benefits of Eurocor's (CE Marked) Genius® MAGIC Cobalt Chromium Coronary Stent System, a state-of-the-art bare-metal stent, which has demonstrated excellent deliverability, conformability and flexibility. GLP pre-clinical trials have shown that the drug/polymer coating is eliminated from the MiStent DES within 45 to 60 days. In addition, the polymer-based coating is fully absorbed in tissue by 90 days in vivo, at which point the bare-metal stent remains. The MiStent DES currently is being evaluated in international clinical studies.

The MiStent Drug Eluting Coronary Stent System is an investigational device. It is not yet approved or available for sale in any market.

About Micell Technologies, Inc.

Micell Technologies™ is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems. Its unique surface and polymer modification technologies enable Micell to precisely and consistently control drug elution and polymer exposure duration, creating the potential for a therapeutic solution to coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell also is developing a drug-coated balloon for vascular interventions. Visit us at www.micell.com.

Micell, Micell Technologies, the Micell Logo, and MiStent are among the trademarks of Micell Technologies, Inc.

Contact: Micell Technologies
Arthur J. Benvenuto, Chairman & CEO
(919) 313-2104


'/>"/>
SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Micell Technologies Rapid Absorption Polymer DES System to be Presented at CRT 2009
2. Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
3. The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008
4. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
5. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
6. Netsmart Technologies Names Michael Valentine as Chief Executive Officer
7. Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine
8. Reportlinker Adds Biomarkers: Technologies and Global Markets
9. Reportlinker Adds Medical Enzymes: Technologies and Global Markets
10. Life Technologies Names Dr. Ora Hirsch Pescovitz to its Board of Directors
11. China Green Material Technologies, Inc. Announces Change of Auditor to Marcum Bernstein & Pinchuk LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... ... July 13, 2017 , ... ... instruments in Orthopedics, has announced today the completion of a major transaction with ... drive organic and external growth. The alliance fuels In’Tech Medical’s service offerings while ...
(Date:7/13/2017)... Philadelphia, PA (PRWEB) , ... July 13, 2017 ... ... and business acceleration programs at Philadelphia’s University City Science Center, Christopher Laing, MRCVS, ... innovation zone in Austin, Texas. Dr. Laing will become the first Executive ...
(Date:7/12/2017)... ... July 12, 2017 , ... Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the ... reagents used for diagnostic tests, announced today that its initial public offering of 1,178,532 ... from the offering will be $7,071,192. , The shares will begin trading on July ...
(Date:7/12/2017)... Frederick, MD (PRWEB) , ... July 12, 2017 ... ... software solutions provider is pleased to announce the release of FreezerPro® version 7.2. ... registration and aliquoting, and query sample information. For ten years, RURO has been ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):